Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/17214
Title: | Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction. | Austin Authors: | Hall, Victoria;Kwong, Jason;Johnson, Douglas F;Ekinci, Elif I | Affiliation: | General Medicine Infectious Diseases Endocrinology Medicine (University of Melbourne) |
Issue Date: | 22-May-2017 | Date: | 2017 | Publication information: | BMJ Case Reports 2017; 2017: bcr-2017-219335 | Abstract: | We describe an adverse outcome in a 70-year-old man with type 2 diabetes mellitus treated with sodium-glucose cotransporter type 2 (SGLT2) inhibitor dapagliflozin. SGLT2 inhibitors act in the proximal tubules to prevent glucose reabsorption and induce urinary glucose excretion, they have been associated with increased risk of urinary tract infection (UTI). Our patient presented to hospital withEscherichia colisepticaemia with positive urine and blood cultures on the background of two previous UTIs occurring post commencement of dapagliflozin in the community. Renal tract ultrasound in hospital revealed incomplete bladder emptying with evidence of urinary stasis, and a postvoid residual volume of 180 mL. His dapagliflozin was ceased, and he has had no further episodes of UTI. This case suggests there may be an increased risk of UTI in patients prescribed SGLT2 inhibitors who also have evidence of bladder outlet obstruction-caution is advised in the prescribing of SGLT2 inhibitors in this setting. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/17214 | DOI: | 10.1136/bcr-2017-219335 | ORCID: | 0000-0003-2372-395X |
Journal: | BMJ Case Reports | PubMed URL: | 28536217 | Type: | Journal Article | Subjects: | Contraindications and precautions Endocrine system Infections Urinary and genital tract disorders Urinary tract infections |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.